Can a cancer drug boost radiation therapy in Hard-to-Treat prostate cancer?
NCT ID NCT06145633
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 2 trial tests whether the drug vorinostat can increase the amount of a target (PSMA) on prostate cancer cells, making them more visible to a radioactive therapy called 177Lu-PSMA-617. The study enrolls 15 men with PSMA-low metastatic castration-resistant prostate cancer who have already tried other treatments. If successful, this approach could expand treatment options for patients whose tumors currently do not respond well to PSMA-targeted radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vorinostat and 177Lu-PSMA-617 (targeted radiation)
What this could lead to
If it works, this could help men with PSMA-low prostate cancer who currently have few options respond to a powerful targeted radiation therapy.
What could go wrong
This is a small early-phase trial with only 15 participants, so results may not apply widely. The combination may also cause side effects like fatigue or low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.